138 related articles for article (PubMed ID: 36282671)
41. Unveiling the link between genetic alterations in gamma secretase and BCMA surface density in multiple myeloma.
Cowan AJ; Green DJ
Br J Haematol; 2024 Feb; 204(2):391-392. PubMed ID: 38014717
[TBL] [Abstract][Full Text] [Related]
42. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
Sellner L; Fan F; Giesen N; Schubert ML; Goldschmidt H; Müller-Tidow C; Dreger P; Raab MS; Schmitt M
Int J Cancer; 2020 Oct; 147(8):2029-2041. PubMed ID: 32270481
[TBL] [Abstract][Full Text] [Related]
43. BCMA-targeting approaches for treatment of multiple myeloma.
Chen Y; Nagarajan C; Tan MS; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):28-36. PubMed ID: 32955181
[TBL] [Abstract][Full Text] [Related]
44. Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
Munawar U; Theuersbacher J; Steinhardt MJ; Zhou X; Han S; Nerreter S; Vogt C; Kurian S; Keller T; Regensburger AK; Teufel E; Mersi J; Bittrich M; Seifert F; Haider MS; Rasche L; Hillenkamp J; Einsele H; Kampik D; Kortüm KM; Waldschmidt JM
Haematologica; 2024 Apr; ():. PubMed ID: 38572568
[TBL] [Abstract][Full Text] [Related]
45. [Cloning, soluble expression and characterization of human sBCMA].
Guan ZB; Cao P; Ye JL; Zhang SQ
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):46-51. PubMed ID: 16572839
[TBL] [Abstract][Full Text] [Related]
46. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
[TBL] [Abstract][Full Text] [Related]
47. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
48. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis.
Mahler MR; Søndergaard HB; Buhelt S; von Essen MR; Romme Christensen J; Enevold C; Sellebjerg F
Mult Scler Relat Disord; 2020 Oct; 45():102391. PubMed ID: 32679525
[TBL] [Abstract][Full Text] [Related]
49. B-cell maturation antigen expression across hematologic cancers: a systematic literature review.
Dogan A; Siegel D; Tran N; Fu A; Fowler J; Belani R; Landgren O
Blood Cancer J; 2020 Jun; 10(6):73. PubMed ID: 32606424
[TBL] [Abstract][Full Text] [Related]
50. Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma.
Cai H; Kakiuchi-Kiyota S; Hendricks R; Zhong S; Liu L; Adedeji AO; Chan P; Schutten MM; Kamath AV; Ovacik MA
AAPS J; 2022 Sep; 24(6):100. PubMed ID: 36127472
[TBL] [Abstract][Full Text] [Related]
51. Robust isolation of malignant plasma cells in multiple myeloma.
Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
[TBL] [Abstract][Full Text] [Related]
52. Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms.
Ndacayisaba LJ; Rappard KE; Shishido SN; Setayesh SM; Tang G; Lin P; Matsumoto N; Hsu CJ; Nevarez R; Velasco CR; Naghdloo A; Yang E; Kelly K; Hicks J; Mason J; Orlowski RZ; Manasanch EE; Kuhn P
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362214
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.
Fang Y; Hou J
Mil Med Res; 2021 Jan; 8(1):9. PubMed ID: 33504363
[TBL] [Abstract][Full Text] [Related]
54. Anti-BCMA antibodies in the future management of multiple myeloma.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Anticancer Ther; 2019 Apr; 19(4):319-326. PubMed ID: 30810049
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
[TBL] [Abstract][Full Text] [Related]
56. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.
Quazi S
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008
[TBL] [Abstract][Full Text] [Related]
57. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
Eckhert E; Hewitt R; Liedtke M
Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
[TBL] [Abstract][Full Text] [Related]
58. Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma.
Rinaldi I; Muthalib A; Edina BC; Wiyono L; Winston K
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884566
[TBL] [Abstract][Full Text] [Related]
59. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
60. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
